A diverse hidradenitis suppurativa cohort: A retrospective cross-sectional study of 13,130 patients from a large US health care system database from 1995 to 2022.

Autor: Young KZ; Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, Michigan., Loveless I; Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, Michigan; Center for Bioinformatics, Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan; Department of Epidemiology and Biostatistics, College of Human Medicine, Michigan State University, East Lansing, Michigan., Su WK; Center for Bioinformatics, Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan; Department of Epidemiology and Biostatistics, College of Human Medicine, Michigan State University, East Lansing, Michigan; Henry Ford Health + Michigan State University Health Sciences, East Lansing, Michigan., Veenstra J; Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, Michigan; Henry Ford Health + Michigan State University Health Sciences, East Lansing, Michigan; Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health, Detroit, Michigan; Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, Michigan; Department of Dermatology, Henry Ford Health, Detroit, Michigan., Yin C; Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, Michigan; Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health, Detroit, Michigan., Dimitrion P; Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, Michigan; Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health, Detroit, Michigan; Cancer Biology Graduate Program, School of Medicine, Wayne State University, Detroit, Michigan., Krevh R; Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, Michigan; Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health, Detroit, Michigan., Zhou L; Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, Michigan; Henry Ford Health + Michigan State University Health Sciences, East Lansing, Michigan; Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health, Detroit, Michigan; Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, Michigan; Department of Dermatology, Henry Ford Health, Detroit, Michigan; Department of Biochemistry, Microbiology, and Immunology, School of Medicine, Wayne State University, Detroit, Michigan; Department of Internal Medicine, Henry Ford Health, Detroit, Michigan., She R; Center for Bioinformatics, Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan., Pan M; Center for Bioinformatics, Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan., Levin AM; Center for Bioinformatics, Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan; Department of Epidemiology and Biostatistics, College of Human Medicine, Michigan State University, East Lansing, Michigan; Henry Ford Health + Michigan State University Health Sciences, East Lansing, Michigan., Young A; Department of Dermatology, Henry Ford Health, Detroit, Michigan., Samir E; Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, Michigan., Dai A; Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, Michigan., Ge J; Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, Michigan., Huggins RH; Henry Ford Health + Michigan State University Health Sciences, East Lansing, Michigan; Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, Michigan; Department of Dermatology, Henry Ford Health, Detroit, Michigan., de Guzman Strong C; Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, Michigan; Henry Ford Health + Michigan State University Health Sciences, East Lansing, Michigan; Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health, Detroit, Michigan; Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, Michigan; Department of Dermatology, Henry Ford Health, Detroit, Michigan., Lim HW; Henry Ford Health + Michigan State University Health Sciences, East Lansing, Michigan; Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, Michigan; Department of Dermatology, Henry Ford Health, Detroit, Michigan., Ozog DM; Henry Ford Health + Michigan State University Health Sciences, East Lansing, Michigan; Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, Michigan; Department of Dermatology, Henry Ford Health, Detroit, Michigan., Hamzavi I; Department of Dermatology, Henry Ford Health, Detroit, Michigan. Electronic address: ihamzav1@hfhs.org., Adrianto I; Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, Michigan; Center for Bioinformatics, Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan; Henry Ford Health + Michigan State University Health Sciences, East Lansing, Michigan; Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health, Detroit, Michigan; Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, Michigan. Electronic address: iadrian1@hfhs.org., Mi QS; Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, Michigan; Henry Ford Health + Michigan State University Health Sciences, East Lansing, Michigan; Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health, Detroit, Michigan; Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, Michigan; Department of Dermatology, Henry Ford Health, Detroit, Michigan; Cancer Biology Graduate Program, School of Medicine, Wayne State University, Detroit, Michigan; Department of Biochemistry, Microbiology, and Immunology, School of Medicine, Wayne State University, Detroit, Michigan; Department of Internal Medicine, Henry Ford Health, Detroit, Michigan. Electronic address: qmi1@hfhs.org.
Jazyk: angličtina
Zdroj: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Nov 10. Date of Electronic Publication: 2024 Nov 10.
DOI: 10.1016/j.jaad.2024.10.073
Abstrakt: Background: Most epidemiological studies of hidradenitis suppurativa (HS) have described homogeneous patient populations.
Objective: To characterize demographics, modifiable health behaviors, and comorbidities of HS patients within a diverse cohort.
Methods: A retrospective cross-sectional study of 13,130 HS patients within a health care system was conducted.
Results: A female sex bias of ∼3:1 in all racial/ethnic subgroups was observed. Black/African American (AA) patients had a lower age at HS diagnosis than White patients (37.1 years vs 39.4 years, P < .001). A higher proportion of Black/AA females than White females with HS had body mass index in the obese range (69.9% vs 56.5%; P = .03). In contrast, fewer Black/AA males with HS had a body mass index in the obese range compared to White males (51.4% vs 61.0%; P < .001). More Black/AA patients than White patients with HS had congestive heart failure (odds ratio (OR) = 2.10, confidence interval (CI) = 1.19-3.78; P < .05), chronic pulmonary disease (OR = 1.34; CI = 1.02-1.78; P < .05), diabetes with chronic complication (OR = 1.73; CI = 1.16-2.60; P < .05), renal disease (OR = 2.66; CI = 1.67-4.34; P < .05), and Charlson comorbidity index score ≥4 (OR = 1.67; CI = 1.09-2.58; P < .05). Furthermore, male patients were more likely than female patients to have renal disease (OR = 2.62; CI = 1.66-4.14; P < .05).
Limitations: A single-center study.
Conclusion: Subgroups of HS patients had significant differences in demographics, risk factors, and comorbid conditions.
Competing Interests: Conflicts of interest Dr Hamzavi is a consultant to AbbVie, Pfizer, Incyte, UCB, Boehringer Ingelheim, Sonoma, Union Therapeutics, Novartis, Jansen, Avita, Galderma; is an investigator for Lenicura, Pfizer, Incyte, Avita, Loreal/Laroche Posay; and is a board member and past-president of the HS foundation and Global Vitiligo foundation. Drs Young, Loveless, Su, Veenstra, Yin, Dimitrion, Krevh, Zhou, She, Pan, Levin, Young, Samir, Dai, Ge, Huggins, de Guzman Strong, Lim, Ozog, Adrianto, and Mi have no conflicts of interest to declare.
(Copyright © 2024 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: